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Summary
Objective: To study the effect of pralnacasan, the orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1 converting
enzyme (ICE), RU 36384/VRT-18858, on joint damage in two mouse models of knee osteoarthritis (OA).
Design: In a collagenase-induced OA model, pralnacasan was given orally by gavage to female Balb/c mice at 0, 12.5, 25 and 50 mg/kg
twice a day. In the second study, pralnacasan was tested in male STR/1N mice, which develop OA spontaneously, by administering
food–drug mixtures ad libitum at concentrations of 0, 700 and 4200 ppm (mg/kg food). OA joint damage was assessed by a semi-quantitative
histopathological score in both studies. In the STR/1N mouse study, urinary levels of collagen cross-links hydroxylysylpyridinoline (HP) and
lysylpyridinoline (LP) were determined by high-pressure liquid chromatography at baseline, after 3 and 6 weeks of treatment and RU
36384/VRT-18858 plasma concentrations was measured after 6 weeks.
Results: In both studies, the mice developed moderate to severe knee joint OA in the medial joint compartments (tibial plateau and femoral
condyle), the non-treated control groups showing median histopathological scores from 18 to 21 of a maximal score of 32. Pralnacasan was
well tolerated. At the doses of 12.5 and 50 mg/kg in collagenase-induced OA and at the high dose of 4200 ppm in STR/1N mice pralnacasan
treatment significantly reduced OA by 13–22%. In the STR/1N mice, urinary levels of HP cross-links and the ratio of HP/LP, which are
indicators of joint damage in OA, were significantly reduced in the high dose group by 59 and 84%, respectively.
Conclusions: The ICE inhibitor pralnacasan reduced joint damage in two experimental models of OA and has the potential to become a
disease-modifying drug for the treatment of OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is one of the most prevalent and costly
chronic diseases in older adults1. Several drugs are cur-
rently under pre-clinical and clinical investigations, but
there are currently no disease-modifying drugs, which
convincingly halt or delay the process of joint destruction.
The current pharmacotherapeutic options are restricted to
a mild-to-moderate relief of OA pain mostly through non-
steroidal anti-inflammatory drugs (NSAIDS) with a growing
use of the novel selective inhibitors of cyclooxygenase-2
(COX-2).
OA is a slowly progressing degenerative disease with
occasional episodes of inflammation. It is mainly character-
ized by the destruction of articular cartilage, osteophytosis
and bony changes such as sclerosis, and cysts in the
subchondral bone of the affected joints2–4.
In OA, as in rheumatoid arthritis, the pro-inflammatory
cytokines interleukin-1 (IL-1) and interleukin-18 (IL-18)
play very important roles as mediators of joint destruction
and pain4–6. Chondrocytes, synoviocytes, inflammatory
cells and bone cells are activated by mechanisms that are
not fully understood to produce and release both IL-1 and
IL-187 and the synovial fluid of OA patients contains el-
evated levels of IL-18 and IL-189. These cytokines are
processed intracellularly from their inactive precursors to
their biologically active, pro-inflammatory forms by IL-1
converting enzyme (ICE, a.k.a. caspase-1) cleavage10.
Activated ICE and enhanced levels of IL-1 and IL-18 are
found in human OA cartilage and synovium7. Via specific
receptors, IL-1 initiates and perpetuates a pathophysio-
logical cascade in a paracrine and autocrine fashion lead-
ing to a strong expression and activation of proteolytic
enzymes, mainly matrix metalloproteinases (MMPs). These
enzymes degrade the collagen and proteoglycan network
of the cartilage matrix, which finally results in severe joint
degeneration5,6. There is recent evidence that IL-18 may
also be involved in this process11. Type I IL-1 receptor
expression is also significantly increased in human OA
chondrocytes and synovial fibroblasts12. In STR/ort mice, a
mutant mouse strain related to the STR/1N strain, which
also develops OA spontaneously, a marked increase of
IL-1 mRNA expression has been demonstrated in the
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affected medial tibial articular cartilage13. In vitro
experiments in bovine cartilage explants revealed that the
endogenous recombinant human IL-1 receptor antagonist
(rhuIL-1Ra) decreased the production of MMPs14, which are
main players in the cartilage destruction in OA. In addition
the intra-articular injection of rhuIL-1Ra in a model of OA in
dogs significantly reduced the joint damage15. IL-1 not only
stimulates the degradation but also inhibits the synthesis of
type II collagen16 and proteoglycans17. There is also evi-
dence that IL-1 and IL-18 are involved not only in the
structural degenerative processes of OA but may also play
an important role in the pathophysiology of OA pain. Periph-
eral inflammation and intrathecal injection of IL-1 in-
creased the expression of COX-2 and the production of the
well-known pain mediator prostaglandin E2 (PGE2) in the rat
CNS and this could be blocked by the tetrapeptide ICE
inhibitor YVAD as well as rhuIL-1Ra18. In addition, a signifi-
cant correlation was found between the levels of IL-18 and
PGE2 in the synovial fluid of OA patients9.
In the present study we investigated the effect of pral-
nacasan, an orally bioavailable pro-drug of the potent,
selective ICE inhibitor RU 36384/VRT-18858, in two murine
models of knee joint OA. In the first, knee joint instability
and subsequent OA were induced in Balb/c mice by intra-
articular injection of a purified bacterial collagenase19
and pralnacasan treatment was given by oral gavage.




Pralnacasan is a pro-drug. Following oral administration
and intestinal absorption, the ethoxy group of pralnacasan
is rapidly hydrolyzed by plasma esterases to yield the
active drug, RU 36384/VRT-18858. The chemical
structures of pralnacasan and RU 36384/VRT-18858 are
shown in Fig. 1.
COLLAGENASE-INDUCED OA IN BALB/C MICE
Animals and experimental protocol
The experimental procedures were approved by the
Animal Welfare Committee of the University of Nijmegen.
Female Balb/c mice (10–12 weeks, 20–25 g, Charles
River) were housed in standard mouse cages (10 animals
per cage) with wood chip bedding. The mice were acclima-
tized after arrival for 2 weeks and had access to standard
mouse food (Sniff-V.1534, Soest, Germany) and acidified
water ad libitum.
Eighty mice were randomized into four treatment groups
(20 animals per group) by the following procedure: after
induction of OA by intra-articular injection of bacterial
collagenase (see method below) the animals were ran-
domly distributed among eight cages and the experimental
groups were then randomly chosen out of the cages.
Induction of OA
The collagenase-induced OA model is based on weak-
ening ligaments in the knee joint due to intra-articular
injection of highly purified bacterial collagenase leading to
increased joint laxity which then results in OA lesions
preferentially in the medial compartments of the
collagenase-injected knee joint (for details of the method
see reference 19). Repeated intra-articular injections of 6 µl
of sterile saline containing 1 unit of the highly purified
bacterial collagenase from Clostridium histiolyticum (Sigma
type VII) into the right knee joint were performed on
experimental days 1 and 3.
Administration of pralnacasan
Treatment commenced on experimental day 4 and con-
tinued for 6 weeks. Three treatment groups (n20 per
group) received either 12.5, 25 or 50 mg/kg pralnacasan
suspended in 1% aqueous carboxymethylcellulose (CMC)
by oral gavage (0.2 ml per animal) twice daily (at 8 AM and
6 PM). One control group (n20) received 1% CMC
(0.2 ml) vehicle only.
Histology
Both right and left knee joints were fixed in formalin for
3 days, decalcified in 5% formic acid and embedded in
paraffin. Serial coronal sections (7 µm) were cut on a
microtome and semi-serially (70 µm apart) stained by fast
green/saffranin-O.
The histological sections were examined by light mi-
croscopy. The OA pathology was evaluated by blinded
Fig. 1. Chemical structure of pralnacasan and its active metabolite, RU 36384/VRT-18858.
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observers by scoring cartilage pathology at all four articu-
lation compartments (medial femoral condyle, lateral fem-
oral condyle, medial tibial plateau, lateral tibial plateau) as
described in Table I and by morphometry of osteophytes.
Five semi-serial sections (70 µm apart) were evaluated
per knee joint. Data are expressed as medians, 25 and 75
quartiles and complete data range per articulation compart-
ment. The contralateral knee joints (not injected with colla-
genase) of eight non-treated control animals were also
scored.
Measurement of osteophytes
The size of osteophytes (µm2) on the medial femoral part
of the knee joint was measured in three semi-serial (70 µm
apart) sections using a computerized image analysis sys-
tem. Osteophytes were measured in sections with two
circular growth plates in the femur to measure osteophyte
formation at a standardized location in the joint.
SPONTANEOUS OA IN STR/1N MICE
Animals and experimental protocol
The experiment was performed according to the regula-
tions of the German Animal Protection Law. Seventy-five
6-week-old male STR/1N mice (strain bred and maintained
at Aventis Pharma, Department of Laboratory Animal
Safety and Welfare, 65926 Frankfurt/Main, Germany) were
randomized to three experimental groups (n25 per
group). The animals were housed individually in standard
mouse cages (room temperature 20–22°C; relative humid-
ity 55–75%; 12 h light/dark cycle) with free access to the
powdered mouse standard food (Sniff R/M-H, Soest,
Germany) and tap water.
To achieve sustained drug exposure, pralnacasan was
blended with the standard food at concentrations of 700
and 4200 ppm and administered ad libitum. The compound
was stable and homogeneously distributed in the food
mixture over 7 days. In a 1-week pilot study the drug-
supplemented mixtures were well accepted and consumed
to the same extent as the non-supplemented control food
(data not shown). Body weight and food consumption of the
animals were measured daily.
Histology
Following the 6-week treatment period the animals were
sacrificed by CO2 inhalation, their left knee joints were
removed and decalcified for 3 days with formic acid (decal-
cifier, Shandon, Frankfurt/Main, Germany), fixed in formalin
and embedded in paraffin. Four sequential coronal sections
of the complete knee joints (7 µm, 0.1 mm apart), stained
with hematoxylin–eosin (H&E) and safranin-O were evalu-
ated by a blinded observer for the degree of histopathologi-
cal joint alterations by using the same semi-quantitative
score as described for the collagenase-induced OA model
in Table I. Again all four articulation compartments (medial
femoral condyle, lateral femoral condyle, medial tibial pla-
teau, lateral tibial plateau) were scored separately. The
same procedure was done in an additional group of 25
six-week-old male STR/1N mice to assess the initial histo-
morphological appearance of left knee joints of this mouse
strain at the starting point of this study.
Measurement of collagen cross-links in urine
Before treatment and after 3 and 6 weeks of treatment,
urine samples were collected to determine the concen-
tration of collagen cross-links hydroxylysylpyridinoline (HP)
and lysylpyridinoline (LP) by keeping the mice overnight in
metabolic cages for 18 h.
The cross-link measurements were performed by high-
pressure liquid chromatography (HPLC) as described pre-
viously23.
In short, after hydrolysis of the urine samples in 6 M HCl,
acid hydrolysates of urine were diluted in acetic acid (final
concentration 50% acetic acid) and injected on an HPLC
system equipped with on-line sample purification on CC31
cellulose using a Prospekt Solid Phase Extractor (Spark,
The Netherlands). The retained cross-links were eluted
from the CC31 material and separated on-line on a cation
exchange column (Whatman Partisil SCX). Eluting cross-
links were detected by a fluorometer at 295(ex)/
400(em) nm (Model FP-920; Jasco, Tokyo, Japan). The
PYD/DPD HPLC calibrator (Metra, Palo Alto, CA) was used
as standard. Creatinine was determined using the Johnson
& Johnson Vitos 250 Clinical Chemistry Slides (CREA).
Urinary cross-link levels are expressed as nmol/mmol
creatinine (for HP and LP) and as the HP/LP ratio.
Table I
Histopathological score of cartilage lesions in the knee joints of female Balb/c mice with collagenase-induced OA
Matrix structure Cellularity
0 Normal 0 Normal
1 Surface irregularities 2 Reduced
3 Superficial fibrillation 5 Strongly reduced
6 Clefts in deep zones 8 Total loss of cartilage and cells
8 Complete loss of cartilage
Matrix staining Subchondral bone
0 Normal to slightly reduced 0 Normal
1 Homogeneously reduced in deep layers 3 Remodeling processes
3 Reduced in the interterritorial matrix, heterogeneous 8 Thickening, strong sclerosis
6 Severely reduced
8 No dye noted
Maximal total score=32
Five semi-serial sections (70 µm apart) were evaluated per knee joint. Data are expressed as mean score per knee joint (0–6). The
contralateral knee joints (not injected with collagenase) of eight non-treated control animals were also scored.
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Measurement of the plasma concentration of RU
36384/VRT-18858
Animals had free access to the drug-supplemented food.
At the end of the 6-week treatment period, heparinized
blood samples were taken by heart puncture immediately
after sacrifice of the animals and the plasma concentration
of the active drug RU 36384/VRT-18858 was measured by
high-pressure liquid chromatography/mass spectrometry
(HPLC/MS).
BIOSTATISTICAL ANALYSIS
Data analysis was conducted by standard methods using
SIGMASTAT statistical software and taking P<0.05 as
significant. The data on body weight, food consumption and
osteophyte size were tested by one-way analysis of vari-
ance (ANOVA) with post-hoc Tukey test. Histopathological
scores were tested using Mann–Whitney rank sum tests
and the data on urinary cross-links using Kruskal–Wallis
one-way ANOVA on ranks with post-hoc Dunn tests. A
linear regression analysis was performed to test for a
possible correlation between body weight vs histopatho-
logical score.
Results
The overall well-being of the animals was good during
both studies and the pralnacasan treatment was well toler-
ated.
COLLAGENASE-INDUCED OA IN BALB/C MICE
Body weight
Pralnacasan treatment did not appear to affect the weight
of the animals. There was no difference in the mean body
weight between the four experimental groups throughout
the study.
OA—histopathology including osteophyte formation
The cartilage lesions were more pronounced on the
medial joint side than on the lateral side, as has been
shown earlier in this OA model. In the lowest dose
(12.5 mg/kg) and highest dose tested (50 mg/kg)
pralnacasan-treated mice had significantly reduced carti-
lage damage in the medial femoral condyle and in medial
tibial plateau in the lowest dose (Fig. 2) when compared
Fig. 2. Effect of the ICE inhibitor pralnacasan on the degree of knee joint damage in female Balb/c mice with collagenase-induced OA. Data
are depicted as box-and-whisker-plots showing medians, 25 and 75 quartiles and complete data range. *Denotes a significant improvement
vs the vehicle-treated OA control group at P<0.05, Mann–Whitney rank sum test (n20 per group).
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with the non-treated control group as indicated by a reduc-
tion of the median histopathological scores by 15–16%
(tibial plateau) and 19–22% (femoral condyle). With the
middle dose (25 mg/kg), no significant difference in the
histopathological score vs the non-treated control
animals was observed. The formation of osteophytes was
most pronounced on the medial side of the joint. The
osteophyte area in the non-treated control group was
71 828±33 730 (mean±standard deviation) and there was
no significant difference in the groups treated with pral-
nacasan.
SPONTANEOUS OA IN STR/1N MICE
Body weight, food consumption, plasma
concentration of the active compound RU
36384/VRT-18858
A pilot study revealed that pralnacasan was sufficiently
stable in the food mixture for at least 1 week and well
tolerated and consumed by the animals. The drug was also
well tolerated in the main study with no signs of toxicity. The
body weight development of the animals was in the normal
range for this mouse strain. The high dose group had a
slightly lower initial body weight at the start of the exper-
imental period.
During the main study, again the food mixture was well
accepted by the mice, except for the highest dose, in which
food consumption was slightly but significantly lower, likely
due to the bitter taste of pralnacasan. The mean daily food
consumption was as follows: untreated control group,
6.06±0.27 g; low dose group, 6.08±0.22 g; high dose
group, 5.83±0.30 (means±standard deviation). Based on
this food consumption and the pralnacasan content of the
food blend (low dose=700 ppm, high dose=4200 ppm), the
average (mean±standard deviation) total daily dose of
pralnacasan is estimated to be 143±10 mg/kg in the low
dose group and 843±68 mg/kg in the high dose group. The
lower food consumption led to a significantly lower mean
body weights in the high dose group of 7, 4 and 6% at
weeks 2, 4 and 6 of the treatment period, respectively.
The plasma concentration of the active compound RU
36384/VRT-18858 (mean±standard deviation) was
0.249±0.164 µg/ml in the low dose group and
2.283±1.249 µg/ml in the high dose group, the latter being
in the pharmacodynamically active and therapeutically rel-
evant range.
OA—histopathology
The STR/1N mice developed typical moderate to severe
histopathological changes of OA with cartilage fibrillations
and erosions, subchondral bone thickening, osteophyte
formation, loss of proteoglycan staining and loss of
chondrocytes predominantly in the medial tibial plateau
(Fig. 3). The non-treated control group showed a median
histopathological score of 19 (maximal score 32). The
effects of pralnacasan on the degree of histopathological






Fig. 3. Coronal histological section (7 µm, H&E) through the knee joint of a 12-week-old male STR/1N mouse showing typical OA changes
in the medial tibial plateau with a marked cartilage erosion (E) and pronounced sclerosis of the subchondral bone (S).
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high dose of pralnacasan (food content 4200 ppm) had a
statistically significantly lower median histopathological
score (−13%) in the medial tibial plateau (P<0.05, Mann–
Whitney rank sum test). With the lower dose of 700 ppm,
pralnacasan had no effect on OA damage.
Collagen cross-links in urine
The changes in collagen HP and LP cross-link concen-
trations during the experimental period are shown in Fig. 5.
At baseline, the mean HP values were not different be-
tween the treatment groups whereas the mean LP value
and the HP/LP ratio of the low dose group were significantly
different from the other two groups. In all three experimen-
tal groups, the HP and LP concentrations decreased sig-
nificantly during the first 3 weeks. However, the HP and LP
values of the high dose group were significantly higher at
week 3 compared to the control group and the low dose
group. At week 6, at the end of the experimental period, the
HP values of the control group and the low dose pral-
nacasan group rose again to a small but significant extent
whereas the HP levels of the high dose pralnacasan
group declined further. In addition, the strong increase in
urinary HP/LP ratio that was observed in both the control
group and the low dose pralnacasan group was completely
absent in the high dose pralnacasan group. This resulted in
a significantly lower median HP cross-link level of 70 nmol/
mmol creatinine (−59%) and a significantly lower median
HP/LP ratio of 6 (−84%) in the high dose group than in the
non-treated control group which had a median HP level
of 171 nmol/mmol creatinine and a HP/LP ratio of 36
(P<0.01, ANOVA).
Discussion
Given the pathophysiologically important role of IL-1
and IL-18 in OA, it is tempting to hypothesize that reducing
the formation and release of these cytokines by ICE inhibi-
tion could offer a useful therapeutic option to slow joint
destruction in OA and ameliorate the signs and symptoms,
such as osteoarthritic pain. This hypothesis is supported by
the finding that the irreversible tetrapeptide ICE inhibitor,
YVAD-CMK, strongly reduced IL-1 and IL-18 in human OA
cartilage explants7. However, like the endogenous IL-1Ra,
this compound is not effective when administered orally.
Pralnacasan is the orally bioavailable pro-drug of RU
36384/VRT-18858 and is the first potent (Ki1.4 nM)
Fig. 4. Effect of the ICE inhibitor pralnacasan on the degree of knee joint damage in male STR/1N mice with spontaneous OA. Data are
depicted as box-and-whisker-plots showing medians, 25 and 75 quartiles and complete data range. *Denotes a significant improvement vs
the vehicle-treated 12-week-old control group in the medial tibial joint compartment at P<0.05, Mann–Whitney rank sum test (n23–25 per
group).
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selective, non-peptidic inhibitor of ICE in phase II clinical
trials for rheumatoid arthritis. RU 36384/VRT-18858 in-
hibits lipopolysaccharide (LPS)-induced IL-1 release
(IC50=0.42 µM) and S. aureus Cowan-induced IL-1 and
IL-18 release (IC50=1.3 and 2.1 µM, respectively) by hu-
man peripheral blood mononuclear cells in vitro. In vivo,
oral administration of pralnacasan (25–100 mg/kg) to mice
inhibited by up to 80% the elevation of serum IL-1 levels
induced by i.p. LPS injections. In the DBA/1 mouse model
of collagen type II-induced arthritis, prophylactic treatment
with pralnacasan (50 and 100 mg/kg p.o. bid) significantly
delayed the onset of forepaw inflammation, and reduced
disease severity by 50–70%. In addition, pralnacasan sig-
nificantly reduced forepaw inflammation and progression of
arthritis when administered to mice with established ar-
thritis reducing the incidence of cartilage damage by ∼60%
and bone erosion by ∼80%, relative to vehicle-treated
mice24.
In the present study pralnacasan treatment significantly
ameliorated the histopathological damage of the medial
knee joint compartments in two mouse models of OA
(collagenase-induced OA in Balb/c mice and spontaneous
OA in STR/1N mice). In the collagenase-induced OA model
no clear dose-response of this structure-modifying effect
was found.
The STR/1N mice are genetically prone to developing a
bilateral instability of the knee joint and a varus deformity of
the hindlegs leading to osteoarthritic lesions, predominantly
in the medial tibial plateau. Male animals show a higher
degree of OA and less variability20–22. Compared with other
animal species, such as the Dunkin Hartley guinea pig, OA
develops very rapidly in these mice and there appears to be
a direct transition from the final stage of skeletal maturation
to the development of OA. The histopathological examina-
tion of a group of untreated 6-week-old animals (Fig. 3)
shows that the mice already have mild OA with a median
score of about 8 on the 32-point scale at baseline.
This phenomenon is also reflected in the dynamics of the
urinary pyridinoline cross-links. High initial levels of urinary
HP cross-links and the significant decline through week 3 of
the experimental period most likely reflect skeletal matura-
tion still ongoing at the beginning of the observation period
followed by an immediate transition towards development
of moderate to severe OA during the following 3 weeks, as
indicated by the significant increase of the HP/LP ratio25.
The HP and LP cross-links, which connect collagen mol-
ecules in matrix of cartilage and bone, have been shown to
be elevated in urine of patients suffering from various
musculoskeletal disorders including OA26,27. They are dis-
cussed as potential biomarkers of OA severity, progression
and therapeutic outcome28. It is known that LP is derived
almost exclusively from bone tissue whereas HP is derived
from both cartilage and bone with the HP/LP ratio giving the
best estimate of the extra-osseous (i.e., cartilage) contribu-
tion. Treatment with the high dose of pralnacasan for 6
weeks reduced the concentration of urinary HP cross-links
and the HP/LP ratio (predominantly reflecting cartilage
degradation). This indicates that pralnacasan treatment
exerts a protective effect against collagen degradation and
complements the histopathological findings. The reason for
the significantly lower baseline values of LP in the low dose
pralnacasan group is unknown, but is considered to have
been a chance event because the animals were allocated
to the experimental groups randomly. The significantly
higher HP and LP values in the high dose group at week 3
may indicate interference with, or delay of, the skeletal
maturation process and suggests that IL-1 may have a
physiological role in this process.
Because the high dose of pralnacasan was consumed
slightly less by the STR/1N mice leading to significantly
lower mean body weight from week 3 of treatment, one
Fig. 5. Effect of the ICE inhibitor pralnacasan on pyridinoline
cross-links in the urine of male STR/1N mice during the develop-
ment of spontaneous OA. Differences between groups were
tested using ANOVA on ranks with post-hoc Dunn tests. Data are
depicted as box-and-whisker-plots showing medians, 25 and 75
quartiles and complete data range. Statistical significance of
differences (P<0.05) compared with control and low dose pral-
nacasan (700 ppm) are indicated by * and #, respectively;
n22–24 per group and time point. C=untreated control; LD=low
dose (700 ppm), HD=high dose (4200 ppm).
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might argue that the protective effect on OA damage was
due to reduced biomechanical stress by the lower body
weight. However, a linear regression analysis showing no
significant correlation between body weight or cumulative
weight gain and joint damage (r2<0.0005) does not support
this hypothesis.
In conclusion, treatment with pralnacasan significantly
reduced the histopathological joint damage in two exper-
imental murine models of OA: collagenase-induced OA and
spontaneous OA in STR/1N mice. These morphological
findings are supported by a strong reduction of collagen
degradation products (pyridinoline cross-links) in the urine
of the STR/1N mice. Overall, the histomorphological effects
of the compound appear to be rather modest. However,
since no data on the effects of disease-modifying reference
compounds have been published in these two specific
animal models, the efficacy of pralnacasan cannot be
judged. Furthermore, it is difficult to translate the effects
observed in this study into clinical relevance for human OA
treatment because no disease-modifying OA drug is avail-
able up until now. The initial Phase I/IIa clinical program
has shown that pralnacasan is well tolerated in healthy
volunteers and patients with rheumatoid arthritis. Pral-
nacasan is currently in clinical Phase II investigation for the
treatment of rheumatoid arthritis and initial support for the
efficacy of ICE inhibition was obtained in a recent 285
patient Phase II trial29. Based on these data, and the data
reported in this pre-clinical study a Phase II clinical program
in OA is now underway to determine whether this orally
active ICE inhibitor is effective against the signs and
symptoms, loss of function and disease progression in OA.
If this therapeutic hypothesis is confirmed, ICE inhibition
with pralnacasan will offer a novel therapeutic option for the
systemic oral treatment of this common, disabling disease.
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